The Center for Breakthrough Medicines (CBM)—a cell and gene therapy focused contract development and manufacturing organization—has entered into a strategic agreement with BioAnalysis (BIA) to provide its clients with direct access to BIA’s analytical testing services.
BIA’s testing capabilities includes the characterization of viral vectors using its proprietary sedimentation velocity approach to analytical ultracentrification, as well as other advanced biophysical methods and analytics.
Through this strategic alliance, CBM gains the expert scientific and data analysis provided by Lake Paul, PhD, founder and principal scientist at BIA, and his team. This provides a deeper resource for CBM clients that are in need of sophisticated assay and method development and a cGMP-compliant laboratory for characterization and advanced analytical methods.
“We could not be more delighted to partner with Dr. Paul and the BIA team – the next generation testing capabilities they bring to the table for CBM’s innovator clients will be a game-changer,” says Dana Cipriano, senior VP of Testing and Analytical Services at Center for Breakthrough Medicines.
“As a CDMO collaborator, BIA has found the perfect match in CBM,” says Paul. “Our testing capabilities are unrivaled, and the sophisticated innovator clientele CBM connects with BIA will be a true differentiator in the CGT analytical testing space.”
Featured image: L to R: Audrey Greenberg, Co-Founder Center for Breakthrough Medicines; Lake Paul, PhD, Founder and President BioAnalysis; Dana Cipriano, Senior Vice President of Testing and Analytical Services, Center for Breakthrough Medicines. Photo: Center for Breakthrough Medicines
